VANGUARD GROUP INC 13D and 13G filings for Cullinan Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 5:39 pm Sale | 2026-03-13 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 0 0.000% | -3,298,504 (Position Closed) | Filing |
| 2026-01-30 1:27 pm Purchase | 2025-12-31 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 3,298,504 5.580% | 355,179 (+12.07%) | Filing |
| 2025-10-30 2:57 pm Sale | 2025-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 2,943,325 4.980% | -55,389 (-1.85%) | Filing |
| 2024-11-12 2:23 pm Unchanged | 2024-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 2,998,714 5.170% | 0 (Unchanged) | Filing |
| 2024-11-04 11:18 am Purchase | 2024-09-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 2,998,714 5.170% | 1,227,271 (+69.28%) | Filing |
| 2024-02-13 5:02 pm Sale | 2023-12-29 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 1,771,443 4.140% | -1,041,522 (-37.03%) | Filing |
| 2023-02-09 11:16 am Purchase | 2022-12-30 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 2,812,965 6.150% | 446,157 (+18.85%) | Filing |
| 2022-02-09 3:43 pm Purchase | 2021-12-31 | 13G | CULLINAN THERAPEUTICS INC CGEM | VANGUARD GROUP INC | 2,366,808 5.420% | 2,366,808 (New Position) | Filing |